Under construction – not a live service
Sign in
Taking people in AustraliaNo phase

Observes Epcoritamab Use in Adults With Two Types of Lymphoma

Studies how the drug epcoritamab works in adults with lymphoma in everyday care.

Key facts

Who runs it
AbbVie
Where
Kingswood, Malvern, and Waratah, AustraliaSee the 3 sitesAlso in 12 other countries, 70 sites
Trial code
Registry title
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Status
Recruiting
People taking part
700 people, planned
Started
28 Mar 2025
Expected to end
Sept 2031
Type of study
Observational
Record updated
17 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diffuse large B-cell lymphoma or follicular lymphoma who are scheduled to get epcoritamab after two or more earlier treatments.

Age
18 years or older
Sex
All sexes can join
Disease stage
Diffuse large B-cell lymphoma or follicular lymphoma that needs treatment after two or more prior lines of therapy (3L+).
Earlier treatment
Two or more prior lines of therapy. The doctor decided on epcoritamab before and independently of this study.

Main reasons for not taking part

  • Any condition listed as a contraindication in the approved local epcoritamab label
  • Taking part in another interventional clinical trial at the same time

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL)
  • Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country
  • The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study

Who cannot take part

  • Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study
  • Any condition included in the contraindications section of the approved local epcoritamab label in the participating country

Where in Australia

Also in 12 other countries, 70 sites

  • Nepean Cancer Centre, Nepean Hospital /ID# 277782Kingswood, AustraliaContact: Rebekah TaylorTaking people
  • Cabrini Hospital Malvern /ID# 277780Malvern, AustraliaContact: Rebekah TaylorTaking people
  • Calvary Mater Newcastle /ID# 277783Waratah, AustraliaContact: Rebekah TaylorTaking people

About the trial

What the trial wants to find out

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.

Read full original descriptionShow less

Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.

Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

The group in the trial

  • Epcoritamab

    Participants will receive epcoritamab as prescribed by their physician according to local label.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)
Plain-language title
Observes Epcoritamab Use in Adults With Two Types of LymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 February 2026